Canaccord Initiates Belite Bio at Buy With $303 Target on Stargardt Therapy
Canaccord cites tinlarebant as the first drug shown to slow Stargardt lesion growth. The PDUFA date is February 12, 2027.
/ 2 items
Canaccord cites tinlarebant as the first drug shown to slow Stargardt lesion growth. The PDUFA date is February 12, 2027.
Belite Bio's tinlarebant demonstrates first successful Phase 3 results for Stargardt disease, reducing retinal lesion growth by 36% in adolescent patients.